And it's true for SPL and ACL. There was a fair bit of upward price pressure coming up to the anticipated phase 3 results. The fiddlers are having a nice party with MSB at the opposite end.
I'm not sure the big money absolutely knew as a fact that the trials had failed in the other two examples. I hope that happens but rarely. More likely they took a calculated punt on the failure stats for late stage drug development. Whereas here for MSB, I'd be quite happy if the big money has inside info in favour of good results. The sooner that is shared with us the happier we'll all be.
MSB Price at posting:
$2.51 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)